Duane Pinto, MD, MPH, FSCAI

Chief Medical Officer
JenaValve
Boston, Massachusetts, United States

Dr. Pinto graduated from Dartmouth College and Georgetown Medical School. He is an Associate Professor of Medicine at Harvard Medical School did all of his clinical training at Beth Israel Deaconess Medical Center. He has served as the cardiology fellowship director, CCU direct and most recently the chief of the interventional cardiology section. He is active in device development involved in trial design and having performed first in human studies for novel mechanical support devices. He recently took a position as Chief Medical Officer for a trancatheter heart valve company, JenaValve. He continues to perform complex coronary, peripheral and structural heart procedures.

Presentation(s):

• CARDIOGENIC SHOCK PAST PRESENT AND FUTURE CLINICAL TRIALS

  Saturday, February 25, 2023
  11:30 AM – 12:10 PM ET

  Disclosure(s): Abbott Vascular, Asahi, Boston Scientific, St Jude, Terumo: Consulting fees or other remuneration (Ongoing); Abiomed: Consultant (Ongoing), University Grants/Research Support (Ongoing); Biotronik: Consultant (Ongoing); BSC: Consultant (Ongoing), University Grants/Research Support (Ongoing); CSL Behring: Consultant (Ongoing), University Grants/Research Support (Ongoing); JenaValve Technology Inc: Employee (Ongoing); Magenta Medical: Consultant (Ongoing); Medtronic Inc: Consultant (Ongoing); NuPulse CV, Inc.: Stock-privately held company (Ongoing)

• Panel Discussion | Is it Feasible to Conduct Meaningful Randomized Clinical Trials for Cardiogenic Shock in 2023 and Beyond

  Saturday, February 25, 2023
  11:54 AM – 12:10 PM ET

  Disclosure(s): Abbott Vascular, Asahi, Boston Scientific, St Jude, Terumo: Consulting fees or other remuneration (Ongoing); Abiomed: Consultant (Ongoing), University Grants/Research Support (Ongoing); Biotronik: Consultant (Ongoing); BSC: Consultant (Ongoing), University Grants/Research Support (Ongoing); CSL Behring: Consultant (Ongoing), University Grants/Research Support (Ongoing); JenaValve Technology Inc: Employee (Ongoing); Magenta Medical: Consultant (Ongoing); Medtronic Inc: Consultant (Ongoing); NuPulse CV, Inc.: Stock-privately held company (Ongoing)

• CARDIOTUBE INTERVIEW: Update on the Jenna Valve technology and clinical trials

  Sunday, February 26, 2023
  11:30 AM – 11:40 AM ET

  Disclosure information not submitted.

• Designated Devices for AI treatment: Industry Perspective

  Monday, February 27, 2023
  3:39 PM – 3:47 PM ET

  Disclosure(s): Abbott Vascular, Asahi, Boston Scientific, St Jude, Terumo: Consulting fees or other remuneration (Ongoing); Abiomed: Consultant (Ongoing), University Grants/Research Support (Ongoing); Biotronik: Consultant (Ongoing); BSC: Consultant (Ongoing), University Grants/Research Support (Ongoing); CSL Behring: Consultant (Ongoing), University Grants/Research Support (Ongoing); JenaValve Technology Inc: Employee (Ongoing); Magenta Medical: Consultant (Ongoing); Medtronic Inc: Consultant (Ongoing); NuPulse CV, Inc.: Stock-privately held company (Ongoing)

• Panel Discussion: Treatment of Aortic Insufficiency | The Next Frontier

  Monday, February 27, 2023
  3:47 PM – 4:10 PM ET

  Disclosure(s): Abbott Vascular, Asahi, Boston Scientific, St Jude, Terumo: Consulting fees or other remuneration (Ongoing); Abiomed: Consultant (Ongoing), University Grants/Research Support (Ongoing); Biotronik: Consultant (Ongoing); BSC: Consultant (Ongoing), University Grants/Research Support (Ongoing); CSL Behring: Consultant (Ongoing), University Grants/Research Support (Ongoing); JenaValve Technology Inc: Employee (Ongoing); Magenta Medical: Consultant (Ongoing); Medtronic Inc: Consultant (Ongoing); NuPulse CV, Inc.: Stock-privately held company (Ongoing)